India's Pharma Opps Hampered by Bureaucracy, Policy
A recent report from the Business Monitor outlines India's strong commercial opportunities for pharmaceutical companies...
A recent report from the Business Monitor outlines India's strong commercial opportunities for pharmaceutical companies, but government issues are increasingly making the country less attractive on many subsectors of pharma, including the regulation of clinical trials.
The Business Monitor offers a risk/reward rating for countries, and India scored a 51.8 out of a possible 100, which is below the regional average for most indicators under industry and country risks. In addition, India ranked 10th behind New Zealand out of the 19 key markets in the Asia-Pacific.
The full release can be read here.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
